One chronic illness, many unlicensed treatments and one pipeline asset: Where do you start with pricing?

A leading pharma company needed to understand the price potential of their novel first-in class asset. Without any direct comparators, they were unsure what price they could achieve and how payers were going to behave.

Inpharmation’s evidence-based approaches provided the perfect solution…

Back to Case Studies

A novel first-in-class asset

Our client, a leading pharma company, wanted an initial landscaping and pricing assessment for a novel first-in-class asset. The asset’s indication was in a chronic illness and, at that time, being treated by a range of off-label medications, all with unpleasant side-effects.

A promising environment for the new asset, but with a few challenges…

With no direct comparators, internal expectations were varied

The off-label treatments were predominantly generic and there were no direct comparators, which raised important questions:

  • What price could their asset realistically achieve?
  • How were payers going to behave?
  • How could our client persuade prescribers to choose their asset?

Global HQ believed the asset was innovative and would command a high price. Local affiliates feared the product would be benchmarked against generics and that a low price was the only option. Reconciling these viewpoints was going to be a challenge.

Inpharmation had the perfect approach that was a little different from the norm…

Download the full Case Study by filling in the form:

By clicking on the “Submit Request” button you are providing consent for us to store your data and contact you. You may withdraw your consent at any time by instructing us at .

View our Privacy Policy for more information.

Please note that Inpharmation literature and case study materials constitute Inpharmation intellectual property and are intended for the pharmaceutical industry. Inpharmation is under no obligation to distribute these materials to non-pharmaceutical industry employees or competitors.

Scroll Top